Read by QxMD icon Read


T I Danilova, V V Danilov, S A Luchinskiĭ, V V Danilov, A V Vasil'chenko
A 4-month course of spasmex (15 mg three times a day) was conducted in 57 females (age 18-69 years, mean age 48 years) suffering from imperative urination manifesting as pollakiuria, imperative urges and urgent urinary incontinence in combination with sexual disorders. After the treatment the score of urination disorders went down from 21.4 to 12.7. Quality of life score decreased from 4.3 to 1.7. Sexual dysfunction diminished from 3.6 to 0.8 points. Clinical data showed that spasmex has a marked effect on m-cholinoreceptors, is well tolerated, has a moderate spasmolytic effect on the smooth muscles of the lower urinary tract...
November 2010: Urologii︠a︡
V V Danilov, T I Danilova, V V Danilov
The analysis of 58 cases of overactive bladder has shown that detrusor activity is not linked with clinical symptoms but is caused by supra segmentary lesion of the nervous system. The clinical picture of overactive bladder fits the proposed neurophysiological model where ischemic damage of the association neuron located in the lumbar spinal marrow triggers miction disorders leading to preganglionary detrusor denervation. Combined therapy with alpha1-adrenoblocker and M-cholinolytic is pathogenetically sound...
July 2010: Urologii︠a︡
P G Shvarts, A S Kadykov, V V Shvedkov, S L Timerbaeva, E V Polevaia, A N Mulach
Overactive bladder (OAB) is observed in such brain diseases as stroke, hypoxic ischemic encephalopathy, Parkinson's disease (PD), multiple sclerosis (MS). Trospium chloride (spasmex) was used in OAB patients with MS (n = 87), stroke (n = 83), encephalopathy (n = 47) and PD (n = 36) in doses from 15 to 45 mg/day in 2 to 36 month courses. The response with minimal side effects was achieved in 94% patients. In addition to basic effects, trospium chloride relieved spastic constipation in patients with stroke, hypersalivation in PD and anal incontinence in MS...
September 2009: Urologii︠a︡
M E Shkol'nikova
No abstract text is available yet for this article.
November 2009: Urologii︠a︡
E B Mazo, G A Babanina
The study included 62 patients (30 males and 32 females, age 19-80 years, duration of the disease 2-28 years) with vertebrogenic disease suffering from urgent, frequent voiding. All the patients have undergone detailed urodynamic and general urological examination monthly before and after treatment. Spasmex was given orally to 16 patients of group 1 (15 mg/day), 24 patients of group 2 (30 mg/day) and 22 patients of group 3 (45 mg/day) once a day for 6 months. It is shown that spasmex in doses 15, 30 and 45 mg was highly effective and well tolerated...
May 2007: Urologii︠a︡
V V Danilov, T I Danilova
Non-invasive uroflowmetric monitoring in females with combined incontinence has demonstrated that hyperactive urinary bladder and stress urine incontinence in females are similar in relation to functional disorders of the low urinary tract both in complete and partial syndrome of imperative urination. In the latter case, when imperative urine incontinence is absent, voiding structure is changed in the same manner, and the patients' preparation for surgical intervention demands long-term treatment with M-cholinolytics...
January 2007: Urologii︠a︡
V V Danilov, I Iu Vol'nykh, T I Danilova, O A Vodop'ianova, N A Kudriakova
The analysis of treatment outcomes in 74 patients with hyperactive urinary bladder (HUB) has shown that duration of the treatment depends on the initial function of the lower urinary tracts. There was a correlation between mean effective therapy and treatment duration. Estimation of this correlation allows prognosis of treatment efficacy and selection of optimal anticholinergic drug for correction of miction disorders. Spasmex proved to be the most adequate drug for long-term treatment due to minimal number of side effects and feasibility to vary dose and regimen of intake...
September 2006: Urologii︠a︡
E B Mazo, G G Krivoborodov, M E Shkol'nikov, G A Babanina, S V Kozyrev, E S Korshunov
The aim of the study was to investigate safety and efficacy of spasmex (trospium chloride) in patients with idiopathic and neurogenic detrusor overactivity. The study included 66 patients with idiopathic and neurogenic detrusor overactivity. The diagnostic scheme consisted of voiding dairy for 72 hours, laboratory tests, ultrasound investigation with measurement of residual urine volume, urodynamic investigation and neurologic examination. The patients were divided into 4 groups: 15 patients with idiopathic detrusor overactivity (DOA), 16 with neurogenic DOA, 23 with combination of DOA with benign prostatic hyperplasia, 12 with overactive bladder without DOA...
July 2005: Urologii︠a︡
Norman R Zinner
The International Continence Society has defined overactive bladder (OAB) as urinary urgency, with or without urge urinary incontinence, usually with urinary frequency and nocturia. Approximately 17% of men and women in the US report OAB symptoms, which can affect quality of life. Trospium chloride, which has recently been introduced in the US as Sanctura, has been prescribed for > 10 years in Europe as, for example, Spasmo-lyt, Regurin and Spasmex. Trospium chloride has been shown to be effective in relieving OAB symptoms, and has a favourable safety profile, showing < 1% difference for all adverse events compared with placebo, except for dry mouth, constipation and headache...
July 2005: Expert Opinion on Pharmacotherapy
V V Danilov, I Iu Vol'nykh, C K Abdullaeva, T I Danilova
The drug spasmex (trospium chloride) having an m-cholinolytic and myotropic spasmolytic action has been used for treatment of enuresis in women with imperative voiding syndrome. Spasmex was given in combination with alpha 1-adrenoblockers to 20 women. The clinical picture was assessed with the original table. Urodynamic alterations were registered by means of home uroflowmeter. Clinical parameters improved 2 times after 4 weeks of the treatment. Mean effective capacity of the urinary bladder increased by 25%...
May 2004: Urologii︠a︡
O Z Klochikhin, D Iu Volkov, E I Vostokova, N I Zhulina
Efficiency of interstitial cystitis (IC) treatment of female outpatients is shown. Combined treatment of IC was supplemented with the drug spasmex which has a peripheral anticholinergic and direct antispastic actions. It quickly relieves irritative symptoms, improves quality of life, shortens temporary disability and lowers the cost of the treatment.
March 2004: Urologii︠a︡
G Carlucci, M M Gentile, S Bartolini, R Anacardio
Ketoprofen lysine salt (Oki Fiale, PG060) is a non steroidal anti-inflammatory agent frequently administered by intramuscular route in association regimen with other drugs, such as steroidal anti-inflammatory, muscle relaxant, local anaesthetic and anti-spastic drugs or vitamins. The aim of this study was to investigate the physicochemical compatibility between ketoprofen lysine salt (Oki Fiale, PG060) and other injectable drugs frequently used in association. Physicochemical properties of ketoprofen lysine salt mixtures with different drugs, including colour, clarity, pH and drug content were observed or measured before and after (up to 3 hours) mixing at room temperature and under light protection...
January 2004: Bollettino Chimico Farmaceutico
D Iu Pushkar', O B Shchaveleva
Overactive urinary bladder (HAUB) is encountered in 16-20% patients with various voiding disorders. Etiologically, detrusor hyperactivity can be neurogenic and idiopathic. We studied efficacy of the antimuscarine drug spasmex in patients with imperative voiding disorders and compared its efficacy and tolerance with those of driptan and detrusitol. 193 female patients with imperative voiding disorders were examined. Spasmex given in a dose of 5 mg 3 times a day for 12 weeks produced a good effect in 56 patients: increased the effective capacity of the urinary bladder, reduced the number of voidings and episodes of incontinence for a day...
July 2003: Urologii︠a︡
E Wolffram
No abstract text is available yet for this article.
October 25, 1968: Münchener Medizinische Wochenschrift
U Heynen
No abstract text is available yet for this article.
May 31, 1970: Zeitschrift Für Allgemeinmedizin
J Schemmann
No abstract text is available yet for this article.
May 1969: Therapie der Gegenwart
M Hasegawa, C Nango, S Kanda, K Miyazaki, T Katsumi
No abstract text is available yet for this article.
April 1971: Hinyokika Kiyo. Acta Urologica Japonica
A Foti, S Penazzo, L Volpe
No abstract text is available yet for this article.
May 31, 1971: Minerva Ginecologica
T Inoue
No abstract text is available yet for this article.
April 1971: Hinyokika Kiyo. Acta Urologica Japonica
N Nishimura, F Hayashi, S Fujii, N Ogura
No abstract text is available yet for this article.
January 1970: Masui. the Japanese Journal of Anesthesiology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"